Genmab A/S (OTCMKTS:GNMSF - Get Free Report) is expected to issue its quarterly earnings data on Wednesday, February 12th. Analysts expect the company to announce earnings of $0.48 per share and revenue of $913.65 million for the quarter.
Genmab A/S Stock Performance
Shares of OTCMKTS GNMSF traded down $4.44 during trading on Friday, hitting $187.73. 7,644 shares of the company traded hands, compared to its average volume of 6,895. Genmab A/S has a fifty-two week low of $187.73 and a fifty-two week high of $323.02. The firm has a market capitalization of $12.40 billion, a price-to-earnings ratio of 18.05 and a beta of 1.04. The business's fifty day moving average is $208.28 and its 200 day moving average is $232.68.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
